{"id":8081,"date":"2025-10-10T17:47:22","date_gmt":"2025-10-10T17:47:22","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8081"},"modified":"2025-10-10T17:47:22","modified_gmt":"2025-10-10T17:47:22","slug":"jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/","title":{"rendered":"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><em>Prospective acquisition of Protagonist Therapeutics centers on oral drug for immune diseases<\/em><\/h4>\n\n\n\n<p>Johnson &amp; Johnson (JNJ) is reportedly in active talks to acquire Protagonist Therapeutics (PTGX), according to people familiar with the matter, a move that sent Protagonist\u2019s shares soaring more than 30 % during afternoon trading. The company\u2019s market value stood at about $4.2 billion as of Thursday\u2019s close. <\/p>\n\n\n\n<p>At the heart of the prospective deal is <strong>icotrokinra<\/strong>, a once-daily oral therapy targeting various immune-mediated conditions such as plaque psoriasis and ulcerative colitis. Under the existing agreement, J&amp;J holds exclusive commercialization rights to the drug. The two firms have been collaborating on development, and the acquisition would effectively give J&amp;J full control over a promising pipeline asset.<\/p>\n\n\n\n<p>The strategic rationale for J&amp;J appears compelling. Its flagship immune-disease drug <strong>Stelara<\/strong> is facing increasing pressure from biosimilars and competitors, putting strain on long-term growth in immunology.  The potential acquisition therefore offers a pathway to replenish and strengthen its next-generation therapeutics portfolio.<\/p>\n\n\n\n<p>Protagonist declined to comment on the acquisition talks, and J&amp;J did not immediately respond to requests for comment. <\/p>\n\n\n\n<p>If completed, the deal would mirror a broader trend among major pharmaceutical players seeking to bolster their pipelines via biotech takeovers. For J&amp;J, securing full ownership of icotrokinra could accelerate its ambitions in oral immunology treatments and improve competitive footing in a fast-evolving market.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/10\/09\/kulr-technology-partners-with-soluna-to-launch-sustainable-bitcoin-mining-operations\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">KULR Technology Partners with Soluna to Launch Sustainable Bitcoin Mining Operations<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prospective acquisition of Protagonist Therapeutics centers on oral drug for immune diseases Johnson &amp; Johnson (JNJ) is reportedly in active talks to acquire Protagonist Therapeutics (PTGX), according to people familiar with the matter, a move that sent Protagonist\u2019s shares soaring more than 30 % during afternoon trading. The company\u2019s market value stood at about $4.2 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":3001,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[]},"categories":[308,361],"tags":[421,831,416,418,832,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8081"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8081"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8081\/revisions"}],"predecessor-version":[{"id":8082,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8081\/revisions\/8082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/3001"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8081"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}